Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 11, Issue 2, Pages 124-130Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2010.11.004
Keywords
-
Categories
Funding
- American Heart Association [SDG 0635007N]
- [PO-1 HL62222]
- [RO-1 HL093028]
Ask authors/readers for more resources
There is a growing consensus that the balance between Angiotensin Type 1 (AT1R) and Angiotensin Type 2 (AT2R) signaling in many tissues may determine the magnitude and, in some cases the direction, of the biological response. Sympatho-excitation in cardiovascular diseases is mediated by a variety of factors and is, in part, dependent on Angiotensin II signaling in the central nervous system. Recent data have provided evidence that the AT2R can modulate sympatho-excitation in animals with hypertension and heart failure. The evidence for this concept is reviewed and a model is put forward to support the rationale that therapeutic targeting of the central AT2R may be beneficial in the setting of chronic heart failure.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available